Algeria ANPP (Agence Nationale des Produits Pharmaceutiques)
A practical guide to Algeria’s pharmaceutical agency, its legal remit and the manufacturing evidence behind a well-controlled submission.

On this page · 11 sections
- 1What Algeria ANPP is: functions, legal basis and supervision
- 2ANPP, registration, homologation and GMP are different concepts
- 3Product and jurisdiction map: establish the category before the route
- 4What the registration directorate assesses and decides
- 5How a manufacturer or exporter approaches ANPP
- 6GMP site records that make dossier statements traceable
- 7A practical evidence model and controlled system handoffs
- 8Three worked cases: evidence gaps, revisions and device enquiries
- 9Control, vigilance and evidence after submission
- 10Common submission mistakes and controlled recovery
- 11Final readiness check: scope, evidence, ownership and follow-up
How does ANPP (Algeria) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What Algeria ANPP is: functions, legal basis and supervision
Algeria ANPP is the Agence Nationale des Produits Pharmaceutiques, Algeria’s public agency for pharmaceutical-product registration, medical-device homologation and quality control.
| Question | Short answer | Authority or qualification |
|---|---|---|
| Full name and common aliases | Agence Nationale des Produits Pharmaceutiques; ANPP; ANPP Algeria | Official agency name; common search variants |
| Country and principal product families | Algeria; pharmaceutical products and medical devices | Official ANPP website description |
| Establishing law | Health Law 18-11, Article 223 | Binding statutory wording |
| Registration, homologation and control | Core public-service functions | Article 225; website describes quality control |
| Supervisory wording | The law and website name different ministerial portfolios | Separate attributions below |
| Manufacturer’s practical starting point | Clarify the product category and regulatory question before preparing the dossier | Illustrative industry practice, not a filing procedure |
What Law 18-11 itself says about ANPP
Three articles of Law 18-11 of 2 July 2018 on health define the statutory core. English glosses below are translations of the French text printed in the Journal Officiel; the French is authoritative.
| Article | French text (JORADP 2018 No. 46) | What it establishes |
|---|---|---|
| 225 | « L’agence assure, notamment une mission de service public en matière d’enregistrement, d’homologation et de contrôle des produits pharmaceutiques et des dispositifs médicaux à usage de la médecine humaine. » | ANPP's public-service mission covers registration, homologation and control of pharmaceutical products and medical devices for human medicine; its missions, organisation and functioning are left to regulation. |
| 230 | « Tout produit pharmaceutique et dispositif médical prêt à l’emploi fabriqué industriellement, importé ou exporté doit faire l'objet, avant sa mise sur le marché, d'une décision d'enregistrement ou d’homologation délivrée par l’agence nationale des produits pharmaceutiques […] après avis des commissions d’enregistrement et d’homologation créées auprès de cette agence. » | Ready-to-use, industrially manufactured, imported or exported pharmaceutical products and devices need an ANPP registration or homologation decision before marketing, issued after the opinion of the registration and homologation commissions. Procedures, renewal, withdrawal and transfer are set by regulation. |
| 242 | « Tout produit pharmaceutique à usage de la médecine humaine, prêt à l’emploi, ainsi que tout dispositif médical ne peuvent être mis sur le marché que s’ils ont été au préalable contrôlés et certifiés conformes au dossier d’enregistrement ou d’homologation. » | Beyond the registration decision, each product may be marketed only after it has been controlled and certified as conforming to its registration or homologation dossier. |
Article 243 of the same law assigns quality control, expertise, monitoring and the recording of adverse effects of pharmaceutical products and devices to ANPP. The detailed procedures that Articles 225 and 230 leave to regulation are found in implementing texts, not in the law itself; check the current text before relying on a specific step.
The ANPP official website supports this functional definition. Its homepage describes a public institution responsible for registration, homologation and quality control of pharmaceutical products and medical devices in Algeria, with vigilance and regulatory follow-up functions.
Law 18-11, Article 223 establishes the agency: “Il est créé une agence nationale des produits pharmaceutiques, dénommée ci-après l’ « agence ».” Translation: A national agency for pharmaceutical products is established, hereinafter referred to as the agency.
Law 18-11, Article 225 states its mission: “L’agence assure, notamment une mission de service public en matière d’enregistrement, d’homologation et de contrôle”. Translation: The agency performs, notably, a public-service mission involving registration, homologation and control.
Law 18-11, Article 224 defines the institution: “L’agence est un établissement public à gestion spécifique doté de la personnalité morale et de l’autonomie financière, placé sous la tutelle du ministre chargé de la santé.” Translation: The agency is a public establishment with specific management arrangements, legal personality and financial autonomy, placed under the supervision of the minister responsible for health.
By contrast, the ANPP website describes supervision by the Ministry of Pharmaceutical Industry. These are distinct attributions: Article 224’s institutional wording and the regulator’s website description. They should not be combined into an assumed transfer date, amending instrument or unchanged present-day ministerial allocation.
This article distinguishes three layers: binding statutory wording; official regulator information, which is not itself legislation; and illustrative industry practice for preparing traceable evidence. Generic software support belongs to the practice layer, not ANPP’s legal remit. For manufacturers, the practical starting point is a clearly framed product question and an evidence owner. The MHRA data-integrity glossary offers comparative context for record controls, not Algerian filing authority. Authorised people remain responsible for review, approval and release decisions.
02ANPP, registration, homologation and GMP are different concepts
For regulatory affairs and manufacturing teams, the practical distinction is between the organisation, the subject of an approval and an internal quality decision. The table separates these concepts; it is not a filing procedure.
| Term | What it identifies | What to keep separate |
|---|---|---|
| ANPP | The agency described above. | The organisation is not itself a product approval. |
| Pharmaceutical-product registration decision | A product-level regulatory decision. | Not establishment approval or batch disposition. |
| Medical-device homologation | The device-related approval concept. | Not pharmaceutical-product registration or a manufacturing-practice term. |
| Pharmaceutical-establishment agrément | Establishment approval under the statutory wording below. | Do not substitute a product decision for establishment approval. |
| BPF or GMP | Bonnes pratiques de fabrication / good manufacturing practice: manufacturing-practice terminology. | Not an ANPP registration decision. |
| Manufacturer’s batch disposition | A controlled quality decision about a particular batch. | Not a regulatory decision about the product. |
Law 18-11, Article 218, first paragraph states: “L’établissement pharmaceutique est une société organisée selon les formes juridiques prévues par le code du commerce et soumise à l’agrément des services compétents du ministère chargé de la santé.”
Translation: A pharmaceutical establishment is a company organised under the legal forms provided by the Commercial Code and subject to approval by the competent services of the ministry responsible for health.
This is the statute’s wording, not a statement identifying today’s establishment-approval authority. In quality-system practice, authorised people make and document batch decisions through a QA disposition step. Keep batch release records and the quality unit’s review process distinct from product-authorisation records.
03Product and jurisdiction map: establish the category before the route
Use Algeria as the jurisdiction for this review. Start with the product’s characteristics and proposed use, not its commercial label. The official descriptions below provide reference points; the practical checks are preparation steps, not legal classification decisions.
| Product or question | Official scope statement | Practical next check |
|---|---|---|
| Human-use pharmaceutical product | The registration directorate’s official description assigns it registration of pharmaceutical products intended for human medicine. | Confirm that the proposed product falls within that description before organising its registration dossier. |
| Medical device | The ANPP website identifies medical devices as a product family with a dedicated appointment channel. | Confirm the individual device category and applicable homologation instructions separately; an appointment channel does not resolve either question. |
| Biologic needing category confirmation | The human-use pharmaceutical description is a starting point for assessment, not a named biologic pathway. | What are its composition, biological origin, presentation and intended therapeutic or diagnostic use? |
| IVD classification question | The broad medical-device reference does not itself settle an individual IVD classification. | What specimen, analyte, user and diagnostic purpose are proposed? Seek confirmation of the applicable category. |
| Borderline supplement, cosmetic, food or chemical | Treat ANPP jurisdiction as a question to resolve, not a conclusion drawn from the label. | Do composition, presentation, claims and intended use place it within an applicable Algerian product definition? |
As industry practice, record intended use, presentation, composition, proposed claims and target market in a dated classification review. Retain the rationale, unresolved questions and responsible reviewer. For tissue-derived products, foreign product classification terminology is background only, not an Algerian determination.
Check current Algerian texts and ANPP instructions before selecting a route. Do not infer a special biologic or cosmetic route from branding. Treat foreign approvals and cooperation arrangements as applicability questions—not presumed reliance mechanisms, recognition entitlements or schedule assumptions.
04What the registration directorate assesses and decides
ANPP’s registration directorate describes its functions on the agency website. That description is regulator guidance, not legislation. For internal planning, distinguish the action being considered—registration, renewal, modification or withdrawal—and confirm its applicable basis before assembling the package.
The registration directorate’s task list includes evaluating scientific documentation concerning pharmaceutical products’ benefits, risks and therapeutic value, together with medical-economic evaluation. Preparation should therefore distinguish the scientific benefit-risk assessment from the economic argument, while keeping their underlying product assumptions consistent.
The directorate’s medicine-pricing function is narrower than independently setting prices: it grants a pricing certificate for medicines subject to registration after the intersectoral economic committee for medicines determines the price.
For unregistered medicines, its temporary-use function is to give an opinion concerning temporary authorisations for use (ATU). This is not a statement that the directorate itself grants those authorisations.
The preparation questions and tracking suggestions below are illustrative industry practice, not a prescribed application checklist.
| Function described by ANPP | Internal preparation question | Result to track |
|---|---|---|
| Registration lifecycle | Which proposed action needs confirmation against current rules? | Applicable basis and resulting decision |
| Scientific evaluation | Do scientific and economic arguments use consistent assumptions? | Assessment questions and approved responses |
| Pricing certificate | Has the committee’s price determination been documented? | Price determination and subsequent certificate |
| Temporary-use opinion | What question needs an opinion concerning an unregistered medicine? | Opinion separately from any authorisation |
When reusing a regulatory dossier prepared for an EMA-related submission, treat it as source material, not proof that Algerian expectations are met. Assign an owner to reconcile product identity, scientific conclusions and economic assumptions before submission.
Check the applicable current text for dossier format, applicant eligibility, fees, decision periods, import permissions and any distinct biologic procedure. Keep these as explicit planning questions rather than inferring a complete filing pathway or estimating regulatory timings from the directorate’s task list.
05How a manufacturer or exporter approaches ANPP
Begin with an internal brief identifying the product, intended Algerian category, manufacturing sites, regulatory question and responsible contacts. Confirm who may submit under the applicable procedure: do not assume that the exporter, manufacturer and distributor can act interchangeably.
ANPP’s website describes the following channels as official guidance:
- E-TASJIL is ANPP’s digital platform for managing registration procedures, as explained in the official homepage FAQ.
- For pharmaceutical-product dossier appointments, the pharmaceutical-product appointment FAQ directs users exclusively to online booking through rdvpp.anpp.dz.
- For medical-device appointments, the medical-device appointment FAQ identifies the separate platform rdvdm.anpp.dz.
Treat appointment booking as scheduling, not as the complete registration procedure. The following is a manufacturer preparation workflow, not an ANPP-mandated sequence; current agency instructions govern the actual filing steps.
- Scope the question. State the action or clarification sought and assign an internal regulatory owner.
- Consult current instructions. Confirm the applicable procedure, submitting party and relevant channel before assembling the package.
- Map evidence. Identify the controlled records supporting each package statement and the people responsible for resolving gaps.
- Review discrepancies. Reconcile conflicting identities, site details and versions; route manufacturing discrepancies through the site’s deviation process where appropriate.
- Approve the package. Have authorised people review its contents and record approval of the exact version intended for transmission.
- Use the relevant official channel and track correspondence. Assign each response or follow-up action an owner and preserve its relationship to the transmitted version.
Keep submission-package identity, transmission evidence and agency correspondence as distinct, linked records. Use the comparison above when interpreting their significance. Do not infer APIs, direct electronic quality-system connections, automatic acceptance or decision-making capabilities from the platforms’ existence. Internal approval remains with authorised company personnel; it is not an agency decision.
- Define scopeRecord product identity, Algerian category question and intended request.
- Check instructionsConfirm the relevant official procedure and responsible applicant.
- Map evidenceConnect dossier statements to controlled manufacturing and quality records.
- Resolve discrepanciesAssign missing references and reconcile conflicting record versions.
- Approve packageObtain authorised internal review of the identified package.
- Use official channelFollow current instructions and preserve evidence of transmission.
- Track follow-upRecord authority correspondence and assign human response ownership.
06GMP site records that make dossier statements traceable
Law 18-11, Article 222 expressly names manufacturing, storage, distribution and dispensing practices: “des règles de bonnes pratiques de fabrication, de stockage, de distribution et de dispensation des produits pharmaceutiques,” Translation: rules of good manufacturing, storage, distribution and dispensing practices for pharmaceutical products.
Consult the current applicable Algerian texts for detailed BPF obligations and inspection arrangements. Do not treat Article 222 as a complete inspection checklist or as evidence that a foreign good manufacturing practice standard has been adopted.
The following is an illustrative site-readiness checklist based on regulated-manufacturing practice. These are evidence candidates selected for the product and regulatory question—not a universal ANPP document list.
| Dossier statement | Candidate site evidence | Reconciliation check |
|---|---|---|
| Manufacturing process and site | Controlled master instructions; site and equipment identifiers | Do site, process version and manufacturing stages match the dossier? |
| Material and product specifications | Approved specification revisions; certificates of analysis | Do material codes, limits, test units and effective dates agree? |
| Analytical methods and results | Analytical method versions; result worksheets; supporting raw records | Was each reported result generated using the identified method version? |
| Batch execution | Executed batch records, including an electronic batch record where used | Do batch identifiers, signatures and execution dates match the represented batches? |
| Stability or validation claims where relevant | Stability results; relevant validation reports | Do formulation, packaging, conditions and process scope support the specific claim? |
| Changes and deviations affecting the represented state | Change records; approved deviation assessments | Are affected batches, dossier statements and implementation dates reconciled? |
Holding a document is not the same as demonstrating that it describes the product, site, process version and batches represented in the dossier. A certificate of analysis for another specification revision may be genuine but unsuitable for the statement being supported. Record stable identifiers, revision status and effective dates; check signatures and preserve links from summaries to supporting raw records. Reconcile test units rather than assuming that visually similar results are directly comparable. A targeted data integrity review can help examine whether the record history supports the reported state.
Assign this internal review to the appropriate authorised quality and regulatory personnel. Quality reviewers should assess manufacturing evidence and unresolved discrepancies; regulatory reviewers should check whether dossier wording accurately represents that evidence. Site quality decisions remain human decisions. Record availability alone is not an ANPP approval criterion established by this checklist.
07A practical evidence model and controlled system handoffs
The following is an illustrative internal model, not ANPP’s data schema or a filing requirement. One regulatory case concerns a defined product scope. Each submission package references specific quality-evidence versions; authority responses attach to the relevant case and package.
Product → Regulatory case → Submission package → Quality-evidence versions; Authority response → Relevant case and package.
| Entity | Illustrative fields and links |
|---|---|
| Product | product_id; defined presentation or configuration |
| Regulatory case | case_id, product_id, market, request_type |
| Quality evidence | record_id, record_version, batch_number where applicable |
| Submission package | case_id, package_version; referenced record_id and record_version pairs |
| Authority response | response_reference, case_id, package_version; affected evidence references |
Use master data management to keep product identifiers consistent, and retain production context when linking batch evidence. Laboratory results, manufacturing records, document-control copies and regulatory working records can move through controlled exports or stable references. Define the owner, source, destination and review step for each exchange; this model implies no connector, portal upload function or validated integration.
- Match product, case, batch and record identifiers at receipt.
- Preserve source units; identify any conversion separately.
- Distinguish source records from translated or reformatted copies.
- Identify the approved revision through document control and record who reviewed the exchange.
These reconciliation points support a data integrity risk assessment. Keep an audit trail of corrections rather than silently replacing values in the regulatory working set.
Separate package completeness from scientific judgement. A software check may be designed to flag an empty identifier or missing reference; it cannot establish scientific sufficiency or confer authority to release product. Those decisions remain with authorised people.
Preserve each submitted package’s identity and evidence-version list when later records change. Use response_reference to connect a regulator question to the exact package and evidence version concerned, then link any revised package without overwriting the earlier submission.
Product
Defines the identity and market under review.
- product_id
- product_name
- market
- classification_status
Regulatory Case
Connects the product, request and accountable owner.
- case_id
- product_id
- request_type
- case_owner
Quality Evidence
Identifies controlled records and relevant batch associations.
- record_id
- record_version
- batch_number
- source_reference
Submission Package
Preserves the reviewed collection and transmission reference.
- package_id
- case_id
- package_version
- evidence_references
- transmission_reference
Authority Response
Links correspondence to the package and follow-up.
- response_reference
- package_id
- response_type
- action_owner
08Three worked cases: evidence gaps, revisions and device enquiries
All three cases are hypothetical internal preparation examples, not accounts of actual applicants, ANPP outcomes or official document requirements. They illustrate internal quality and regulatory-operations reasoning.
Case 1: Three missing evidence associations
Assume six batches and four selected evidence associations per batch: executed batch record, certificate of analysis, applicable method version and deviation assessment. The planned total is 6 × 4 = 24 batch-to-evidence associations. With three missing, 21 of 24 are mapped: 21 ÷ 24 × 100 = 87.5%. The unit is an association, not a unique document; one controlled method may support several batches.
Assume the gaps concern a batch record, method version and deviation assessment. Assign manufacturing to locate the executed record, QC to establish the applicable method version, and QA to assess the deviation linkage. Use a requirements traceability register to track closure. Mapping progress does not establish scientific adequacy: reviewers still assess relevance and support for each claim. The percentage is an internal tracking metric, not an ANPP completeness threshold or approval probability. Deliverable: an assigned evidence-gap list.
Case 2: Specification revisions disagree
Assume the package references specification revision 03 while the site uses revision 04. Reviewers establish which revision describes the batches and claims in scope, assess the change, and document the rationale rather than substituting the newest file automatically. Preserve both the historical package and the reviewed correction, with the decision traceable through an audit trail review workflow. This example assigns no regulatory variation category. Deliverable: a reconciled version decision.
Case 3: IVD appointment confirmation
Assume a manufacturer has an in vitro diagnostic (IVD) product and a device-appointment confirmation. Apply the earlier medical device classification and record-type distinctions: keep the confirmation identified as an appointment record. The regulatory owner records unresolved questions about the applicable product category, current filing instructions, correct evidence scope and status of any authority response. Track each question separately without inferring an agency decision or response time. Deliverable: a documented classification enquiry.
09Control, vigilance and evidence after submission
Law 18-11, Article 243 identifies control-and-vigilance functions and attributes them to ANPP. Two separate French phrases distinguish the functions from their institutional attribution:
- Named functions: “Le contrôle de la qualité, l’expertise, la veille et le recensement des effets indésirables induits par l’usage”. Translation: Quality control, expert assessment, vigilance and recording adverse effects arising from use.
- Agency attribution: “assurés par l’agence nationale des produits pharmaceutiques.” Translation: carried out by the national agency for pharmaceutical products.
Practical evidence preparation is distinct from statutory reporting duties. For a question concerning a batch, test result or reported event, maintain a retrievable enquiry record connecting product identity, affected batches, applicable specification versions, relevant test results, investigation records and a named response owner.
Connect complaint management records to the investigation, and use batch traceability to establish which lots are implicated. Distinguish confirmed facts from unresolved questions; preserve the response version and supporting records so an authorised reviewer can explain what was known when the response was approved.
Check current official instructions for reporting destinations, responsibilities and deadlines. Do not treat this evidence-retrieval checklist as a reporting procedure or wait for a complete investigation before checking whether reporting action is needed.
10Common submission mistakes and controlled recovery
Use these practical exception controls within document control; they are not an ANPP-prescribed procedure. Assign a reviewer and retain the recovery record.
| Failure | Detection control | Recovery action | Responsible reviewer |
|---|---|---|---|
| Conflicting product identifiers | Cross-check package identifiers against controlled source records. | Reconcile discrepancies; document the reviewer’s conclusion and affected documents. | Regulatory lead |
| Superseded evidence | Compare revisions with controlled source records. | Reconcile versions; replace superseded copies and document the reviewer’s conclusion. | Document-control owner |
| Untraceable translation | Check original-to-translation linkage and revision. | Retain the original, correct the controlled derivative and assess the affected package. | Qualified translation reviewer |
| Missing transmission evidence | Review acknowledgements and transaction logs. | Preserve package and transaction evidence; establish current status and seek clarification through the relevant official channel, rather than defaulting to duplicate filing. | Submission owner |
| Unresolved assumptions about pricing, import or decision status. | Compare assertions with the relevant decision or correspondence. | Apply the earlier pricing and decision distinctions. Record import uncertainty separately; resolve against applicable current rules, not inference from another document. | Regulatory lead |
Use a data-integrity risk assessment to assess downstream impact. Escalate recurring failures for corrective and preventive action; route controlled revisions through change control before an authorised reviewer closes the exception.
11Final readiness check: scope, evidence, ownership and follow-up
Use these internal project-control questions at the package review:
- Is the classification question documented, with its rationale and unresolved boundaries?
- Are current procedural instructions identified and reflected in the working SOP?
- Is submission responsibility confirmed and recorded?
- Does the package have a controlled identifier, revision and contents list?
- Are evidence references reconciled to the intended record versions?
- Does every open issue have an owner, priority and target date?
- Has an authorised internal reviewer documented the review outcome, including relevant change-control decisions?
- Is a correspondence owner assigned to track enquiries, responses and follow-up?
The FAQs apply these controls to specific decisions. Keep the earlier distinction between internal readiness and authority decisions in view. Next, resolve the highest-impact uncertainty before treating the package as internally ready.
Frequently asked questions
Q.Why do Law 18-11 and ANPP’s website name different supervising ministries?+
A difference in ministry names should prompt a check of the current legal position, not an assumption that either name can be substituted throughout a dossier. Confirm the applicable supervision provisions and the ministry designation required for the specific correspondence or filing. As a document-management practice, preserve historical titles in historical records and use confirmed current titles in new documents. Keep that distinction in your document control instructions rather than silently rewriting earlier approvals.
Q.How should a foreign GMP certificate or product approval be assessed when planning an Algerian submission?+
As a submission-planning practice, assess each foreign document against the proposed Algerian product, manufacturing site and activities. Check its issuer, scope, validity, dosage form, named addresses and any restrictions; then confirm its intended use with the relevant Algerian contact. Do not assume that a manufacturing certificate and a product approval answer the same question. Link the assessment to your cGMP records and, where a contractor holds the document, your CMO/CDMO management file.
Q.How should a biologic, IVD or borderline supplement be scoped before choosing a filing route?+
Prepare a classification brief before selecting a route: composition, intended purpose, claims, presentation, mode of action and proposed users. For a biologic, describe its biological source and manufacturing process; for an IVD, specify the specimen, analyte and intended diagnostic use; for a borderline supplement, capture the exact proposed claims. These are planning practices, not Algerian classification rules. Use medical-device classification and technical-file principles to organise questions, then obtain a product-specific route confirmation.
Q.What role does the registration directorate describe for temporary use of an unregistered medicine?+
The registration directorate’s mission statement describes its role as giving an opinion on temporary authorisations for the use of unregistered medicines, identified as ATU. That wording describes an advisory function; it should not be expanded into a claim that the directorate itself grants every such authorisation. As a planning practice, ask who makes the applicable decision and what conditions govern the proposed use. Track the opinion, decision and supporting correspondence separately within the QA process.
Q.Which factory records help when one dossier covers several manufacturing batches?+
As a dossier-support practice, build a batch-to-document index linking each batch identifier to its manufacturing record, material lots, applicable specifications, test results, deviations and disposition decision. Identify which batches support validation, stability or other dossier statements instead of treating every batch as interchangeable. A batch record supplies the execution history; bulk-to-pack traceability helps connect that history to packaged presentations. Preserve the version and date of each supporting record so reviewers can reconstruct the submitted evidence.
Q.How should pricing, registration, import questions and batch disposition be tracked without conflating their status?+
Use separate status fields, owners and supporting documents for each workstream. ANPP’s registration directorate describes issuing a medicine pricing certificate after the intersectoral economic committee determines the price. As an operational practice, record that certificate separately from registration correspondence, import-related answers and the site’s batch decision. Define precisely what closes each item, including any conditions still outstanding. Keep the QA disposition step under authorised human approval, with cross-references rather than one ambiguous “approved” flag.
Primary sources
Want to see how ANPP (Algeria) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
